Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Antidote.me

Explore full profile

Transforming the way that sponsors and patients connect in order to accelerate medical research

North Miami Beach, United StatesFounded 2010Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2021
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Antidote.me and the history behind them.

About Antidote.me

Antidote Technologies, Inc. operates in the healthcare sector, focusing on bridging the gap between patients and clinical research. The company offers precision recruitment services to pharmaceutical sponsors, helping them fill clinical trials faster and more efficiently. This service addresses a critical issue in medical research, where over 80% of studies are delayed due to a lack of participants. By leveraging advanced algorithms and patient data, Antidote matches patients with relevant clinical trials, ensuring that both parties benefit. The business model is primarily B2B, targeting pharmaceutical companies and research organizations who pay for the recruitment services. Revenue is generated through service fees and potentially performance-based incentives. Antidote also serves patients by providing a platform where they can easily find and enroll in clinical trials that match their medical conditions. This dual approach not only accelerates medical research but also offers patients access to cutting-edge treatments. Keywords: clinical trials, patient recruitment, precision recruitment, medical research, pharmaceutical sponsors, healthcare technology, patient matching, research acceleration, B2B services, clinical trial enrollment.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2010
Headquarters
North Miami Beach, United States
Employees
24
Open positions
None listed
Dealroom signal
62.3/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Sustainable Development Goals, UKis Digital and technologies, Clinical Trials, Tech for Biotech and Pharma, uk is8 digital and technologies, uk is8 life sciences, AI Drug Discovery
Business model
Marketplace & ecommerce

Latest news

Press, funding announcements and product moves mentioning Antidote.me.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jun 2021 $23M $92M Smedvig Capital · Merck Global Health Innovation Fund · LBO France · Octopus Ventures
EARLY VCOther financing Sep 2017 $11M $44M Octopus Ventures · Smedvig Capital · Merck & Co.
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021
2020
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Antidote.me website traffic

Latest recorded traffic for Antidote.me is 53K monthly website visits, down 38.4% over the last three months. Antidote.me's team declined 7.7% over the past year.

Latest monthly visits53K 3-month web change-38.4% 1-year team growth-7.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Series A3 investors entered at this stage

Series B and later2 investors entered at this stage

  • Merck Global Health Innovation Fund
  • LBO France
Team profiled 27 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States57.1%
🇬🇧 United Kingdom21.4%
🇨🇦 Canada14.3%
🇧🇬 Bulgaria7.1%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Antidote.me on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Antidote.me’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.